GI Innovation, Inc. (KOSDAQ:358570)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,710
-930 (-6.35%)
Mar 28, 2025, 3:30 PM KST
12.29%
Market Cap 607.42B
Revenue n/a
Net Income n/a
Shares Out 44.30M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 806,195
Average Volume 1,277,245
Open 14,640
Previous Close 14,640
Day's Range 13,200 - 14,640
52-Week Range 7,490 - 18,290
Beta 0.55
RSI 40.31
Earnings Date n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The company was founded in 2017 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 358570
Full Company Profile

News

There is no news available yet.